SQZ Biotechnologies Reports Second Quarter 2023 Financial Results and Recent Portfolio Updates
Phase 1 SQZ-AAC-HPV-101 Clinical Trial Observed a Confirmed Complete Response in the First Patient and a Best Overall Response of Stable Disease in Two Additional Patients in the Lowest-Dose Cohort; Anticipate Interim Data in the Fourth Quarter of 2023SQZ® eAPC Phase 1/2 Trial Monotherapy Enrollment Complete; Antici...
Howard Bernstein Programs For Partnership Company Actively Exploring Strategic Partnerships Biotechnologies Company Company Annual Report On Form Exchange Commission
Source: pharmiweb.com